Drug Profile
PNQ 103
Alternative Names: PNQ-103Latest Information Update: 17 Jun 2020
Price :
$50
*
At a glance
- Originator Advinus Therapeutics
- Developer Impetis Biosciences
- Class Antianaemics; Antiasthmatics; Antifibrotics; Small molecules
- Mechanism of Action Adenosine A2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Allergic asthma; Pulmonary fibrosis; Sickle cell anaemia
Most Recent Events
- 17 Jun 2020 PNQ 103 is still in preclinical trials for Sickle cell anaemia, Pulmonary fibrosis and Allergic asthma, in India (PO)
- 17 Jun 2020 PNQ 103 is available for licensing as of 17 Jun 2020. https://impetisbiosciences.com/
- 17 Jun 2020 Impetis Biosciences has patent protection for PNQ 103 in USA, Europe and Japan